Authors:
Partsch, H
Niessner, H
Bergau, L
Blattler, W
Cerny, J
Gerlach, H
Haas, P
Haas, S
Hirschl, M
Korninger, H
Kyrle, P
Landgraf, H
Mahler, F
Minar, E
Pabinger, I
Prinz, A
Rabe, E
Radner, A
Ramelet, AA
Schobersberger, W
Schuller-Petrovic, S
Stoberl, C
Zinnagl, N
Citation: H. Partsch et al., Traveller's thrombosis 2001, PHLEBOLOGIE, 30(4), 2001, pp. 101-103
Authors:
Rintelen, C
Pabinger, I
Bettelheim, P
Lechner, K
Kyrle, PA
Knobl, P
Schneider, B
Mannhalter, C
Citation: C. Rintelen et al., Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation, EUR J HAEMA, 67(3), 2001, pp. 165-169
Authors:
Kuhle, S
Lane, DA
Jochmanns, K
Male, C
Quehenberger, P
Lechner, K
Pabinger, I
Citation: S. Kuhle et al., Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism, THROMB HAEM, 86(4), 2001, pp. 1007-1011
Authors:
Jansen, M
Schmaldienst, S
Banyai, S
Quehenberger, P
Pabinger, I
Derfler, K
Horl, WH
Knobl, P
Citation: M. Jansen et al., Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb), BR J HAEM, 112(1), 2001, pp. 91-97
Authors:
Deguchi, H
Fernandez, JA
Pabinger, I
Heit, JA
Griffin, JH
Citation: H. Deguchi et al., Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway, BLOOD, 97(7), 2001, pp. 1907-1914
Authors:
Gandrille, S
Borgel, D
Sala, N
Espinosa-Parrilla, Y
Simmonds, R
Rezende, S
Lind, B
Mannhalter, C
Pabinger, I
Reitsma, PH
Formstone, C
Cooper, DN
Saito, H
Suzuki, K
Bernardi, F
Aiach, M
Citation: S. Gandrille et al., Protein S deficiency: A database of mutations - Summary of the first update, THROMB HAEM, 84(5), 2000, pp. 918-918
Authors:
Male, C
Lechner, K
Speiser, W
Pabinger, I
Citation: C. Male et al., Transient lupus anticoagulants in children: Stepwise disappearance of diagnostic features, THROMB HAEM, 83(1), 2000, pp. 174-175
Authors:
Eichinger, S
Kyrle, PA
Pabinger, I
Lechner, K
Citation: S. Eichinger et al., The risk of recurrent venous thromboembolic disease - implications for treatment, ACUTE PULMONARY EMBOLISM, 2000, pp. 155-160
Authors:
Rintelen, C
Mannhalter, C
Lechner, K
Eichinger, S
Kyrle, PA
Papagiannopoulos, M
Schneider, B
Pabinger, I
Citation: C. Rintelen et al., No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene, BL COAG FIB, 10(2), 1999, pp. 101-105
Authors:
Meidlinger, P
Knobl, P
Jager, U
Gisslinger, H
Pabinger, I
Weltermann, A
Lechner, K
Geissler, K
Citation: P. Meidlinger et al., Granulocyte colony-stimulating factor-supported combined immunosuppressivetherapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) inpatients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment, ANN HEMATOL, 78(7), 1999, pp. 299-304
Authors:
Winkler, UH
Norris, L
Gaspard, U
van Enk, A
Mishell, D
Voncken, D
Klipping, C
David, J
van den Ende, A
Jespersen, J
Pabinger, I
MacRae, K
Crosignani, P
Skouby, S
Citation: Uh. Winkler et al., An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables - Outline of the protocol, CONTRACEPT, 59(6), 1999, pp. 345-355